Frontiers in Cell and Developmental Biology (Jan 2019)

Statins and Histone Deacetylase Inhibitors Affect Lamin A/C – Histone Deacetylase 2 Interaction in Human Cells

  • Elisabetta Mattioli,
  • Elisabetta Mattioli,
  • Davide Andrenacci,
  • Davide Andrenacci,
  • Antonello Mai,
  • Sergio Valente,
  • Joke Robijns,
  • Winnok H. De Vos,
  • Cristina Capanni,
  • Cristina Capanni,
  • Giovanna Lattanzi,
  • Giovanna Lattanzi

DOI
https://doi.org/10.3389/fcell.2019.00006
Journal volume & issue
Vol. 7

Abstract

Read online

We recently identified lamin A/C as a docking molecule for human histone deacetylase 2 (HDAC2) and showed involvement of HDAC2-lamin A/C complexes in the DNA damage response. We further showed that lamin A/C-HDAC2 interaction is altered in Hutchinson-Gilford Progeria syndrome and other progeroid laminopathies. Here, we show that both inhibitors of lamin A maturation and small molecules inhibiting HDAC activity affect lamin A/C interaction with HDAC2. While statins, which inhibit prelamin A processing, reduce protein interaction, HDAC inhibitors strengthen protein binding. Moreover, treatment with HDAC inhibitors restored the enfeebled lamin A/C-HDAC2 interaction observed in HGPS cells. Based on these results, we propose that prelamin A levels as well as HDAC2 activation status might influence the extent of HDAC2 recruitment to the lamin A/C-containing platform and contribute to modulate HDAC2 activity. Our study links prelamin A processing to HDAC2 regulation and provides new insights into the effect of statins and histone deacetylase inhibitors on lamin A/C functionality in normal and progeroid cells.

Keywords